PF-05230907

BIOLOGICAL3 trials

Sponsors

Pfizer

Conditions

HealthyIntracerebral Hemorrhage

Phase 1

A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers

CompletedNCT01897142

Start: 2013-09-30End: 2015-03-31Updated: 2016-04-22

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

CompletedNCT02537002

Start: 2015-09-30End: 2016-03-31Updated: 2016-04-29

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

TerminatedNCT02687191

PfizerIntracerebral Hemorrhage

Start: 2016-11-30End: 2018-01-31Updated: 2019-04-17

Related Papers

Phase 1b Study to Evaluate Safety, Tolerability, and Maximum Tolerated Dose of PF-05230907 for Intracerebral Hemorrhage

Stroke2020-12-045 citations

Zymogen-like FXa Variant As a Short-Acting Warfarin Reversal Agent: Pre-Clinical Evaluation and Mechanism of Action

Blood2014-12-062 citations